Biogen stock heads into the open after a 1.6 percent slide

At the close on September 18, 2026, Biogen stock finished at USD 215.50 on Nasdaq, down 1.62 percent, as investors weighed fresh guidance and Japan's approval of the Leqembi Pen. The session saw volume of 2,630,000 shares and left the stock near the top of its 52-week range.

Biogen stock closed at USD 215.50 on Nasdaq on September 18, 2026, representing a decline of 1.62 percent from the prior session. The move came as the shares continued to trade near the upper end of their 52-week range between USD 135.39 and USD 225.80, highlighting that the recent pullback followed a strong recovery phase.

September 18, 2026 in numbers

Biogen Inc. (ISIN US09062X1037, Nasdaq: BIIB) finished trading on Nasdaq on September 18, 2026, at USD 215.50, down 1.62 percent compared with the previous close, with an intraday range between a low of USD 215.41 and a high of USD 219.91 and trading volume of 2,630,000 shares per exchange data cited in an article by MarketBeat. As reported by Ad-hoc-news, the session left Biogen shares within a 52-week range of USD 135.39 to USD 225.80, corresponding to a market capitalization of USD 31.84 billion as of that closing price. According to data reproduced in a S&P 500 constituents overview at Cinco Dias, Biogen's 1.52 percent decline on September 18, 2026, slightly lagged the broader index, which added 0.17 percent the same day, underscoring a stock-specific drag compared with the modest market gain.

Ad-hoc-news reported that Biogen shares reacted as investors digested fresh company guidance and the regulatory approval of the Alzheimer therapy Leqembi Pen in Japan, indicating that updated expectations and the new formulation's approval were key drivers of the trading day. The same report noted that the Nasdaq-listed stock's positioning near its 52-week high range, combined with the guidance update, contributed to profit-taking pressure despite the positive regulatory news backdrop.

Today’s drivers for Biogen on September 21, 2026

Looking ahead to today, investors in Biogen are likely to continue to focus on how the newly approved Leqembi Pen in Japan and the recent guidance changes translate into future revenue and profitability, with the regulatory development and outlook comments detailed in the report by Ad-hoc-news. Broader market conditions may also shape sentiment, as a wrap of United States equity trading on September 18, 2026, cited by 21st Century Business Herald highlighted that the S&P 500 index closed up 0.17 percent while the Nasdaq Composite gained 0.39 percent on September 18, 2026, suggesting a constructive backdrop for large-cap growth and health care names as trading resumes today.